Legal Opinion

Impax Labs., Inc. v. Lannett Holdings Inc.

District Court, D. Delaware

Decided March 29, 2017No. Nos. 14-CV-984, 14-cv-999 (RGA)PublishedCited by 2 opinions

1Opinion of the Court

Trial Opinion

Andrews, U.S. District Judge

Plaintiffs Impax Laboratories, AstraZ-eneca UK (“AZUK”), and AstraZeneca AB (“AZAB”) brought suit against Defendants Lannett Holdings, Inc. and Lannett Company, Inc. for infringement of U.S. Patent Nos. 6,750,237 and 7,220,767 (“the Dearn patents”).

*1028The Dearn patents claim invention of a nasal formulation for zolmitriptan. Zolmi-triptan is a member of the triptan class of drugs, which treat migraines.

AstraZeneca Pharmaceuticals LP holds New Drug Application No. 21450 for zolmi-triptan nasal spray. Zolmitriptan nasal spray, as well as other zolmitriptan…

2Cases cited23 opinions

Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
W.L. Gore & Associates, Inc., Appellant/cross-Appellee v. Garlock, Inc., Appellee/cross-AppellantCourt of Appeals for the Federal Circuit · 1983
Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007

18 more not listed; retrieve them via the Exa API.

3Cited by2 opinions

Impax Laboratories Inc. v. Lannett Holdings Inc.Court of Appeals for the Federal Circuit · 2018
Galderma Labs. L.P. v. Teva Pharm. United States, Inc.District Court, D. Delaware · 2019